ARTICLE | Company News
NeoTherapeutics, NDDO Research Foundation deal
January 8, 2001 8:00 AM UTC
NEOT subsidiary NeoOncoRx Inc. signed a letter of intent to acquire the EO9 indolequinone anticancer agent, renamed Neoquin, and its analogs from the foundation. ...